23 03, 2018

Psychopharmacology Bulletin Featured in EBSCO’s Latest Edition of New & Notable

By |2018-03-23T15:32:55-07:00March 23rd, 2018|MedWorks, We Know Psychiatry|0 Comments

We are excited to announce that MedWorks Media's flagship journal, Psychopharmacology Bulletin, has been featured in EBSCO's latest issue of New & Notable. MedWorks Media (Psychopharmacology Bulletin) has partnered with EBSCO Information Services for over 15 years. EBSCO Information Services provides a complete and optimized research solution comprised [...]

22 03, 2018

The Use of Gabapentin in Acute Alcohol Withdrawal

By |2021-11-11T17:01:33-08:00March 22nd, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Gabapentin’s anxiolytic and sedative properties along with its overall safety profile suggest that it may be a viable adjuvant to lorazepam in the management of acute alcohol withdrawal. By Christopher Wilming, Mariah Alford, and Lynnette Klaus On average, the required benzodiazepine dosage was lower with concomitant use of gabapentin in [...]

19 03, 2018

First for Big Pharma: Novartis Strikes Deal with Canadian Company to Distribute Medical Marijuana Products

By |2021-11-11T17:02:06-08:00March 19th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

In what may be the first foray by Big Pharma into the sale of medical marijuana products, Novartis has struck a deal with a Canadian company that sells medical cannabis products not only in its home country but also in Europe. Nanaimo, British Columbia-based Tilray announced today that it has a binding [...]

11 03, 2018

Lurasidone (Latuda) Gains FDA Approval for Bipolar Depression in Kids

By |2021-11-11T17:02:48-08:00March 11th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for lurasidone (Latuda) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression) in children and adolescents aged 10 to 17 years. Lurasidone, a serotonin dopamine antagonist, is already approved in the [...]

5 03, 2018

Viewpoint: Treating Bipolar Disorder Like Cancer

By |2021-11-11T17:03:00-08:00March 5th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

In a fascinating note in today's Journal of the American Medical Association (JAMA), Robert M. Post of the George Washington University School of Medicine attributes stigma as one of the main factors contributing to inadequate recognition and treatment of recurrent mood disorders, including unipolar depression and bipolar disorder. "This Viewpoint describes an [...]

1 03, 2018

Top 5 Articles of February 2018

By |2021-11-11T17:03:19-08:00March 1st, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Top 5 Articles of February 2018 Updated for 2018 Dosing and Monitoring: Child and Adolescent Psychotropic Criteria For Children And Adolescents Psychotropic Drugs: Side Effects And Teratogenic Risks Recommended Clinical Monitoring Of Children And Adolescents For Psychotropic Drugs Internet Resources READ MORE A Pilot Evaluating Clinical Pharmacy Services in an [...]

12 02, 2018

Married to an Alcoholic? You, Too, Are at Risk

By |2021-11-11T17:03:32-08:00February 12th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The increase in risk for alcohol use disorder (AUD) in a married individual following a diagnosis of alcoholism in the other spouse is "large and rapid," according to researchers writing recently in JAMA. The causes of this association remain unclear. Population-wide Swedish registries were used to identify individuals born in [...]

7 02, 2018

Vitamin and Mineral Supplements: What Clinicians Need to Know

By |2021-11-11T17:03:44-08:00February 7th, 2018|Brief Bulletins from the Field, We Know Psychiatry|3 Comments

By JoAnn E. Manson, and Shari S. Bassuk Dietary supplementation is approximately a $30 billion industry in the United States, with more than 90 000 products on the market. In recent national surveys, 52% of US adults reported use of at least 1 supplement product, and 10% reported use of at least 4 such [...]

29 01, 2018

Is Methamphetamine-Induced Psychosis Reversible?

By |2018-01-29T11:21:52-08:00January 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|4 Comments

According to an evidence-based review in the journal Current Psychiatry, the answer is a qualified "Maybe." Chronic methamphetamine use can induce pathological brain changes in the brain. Users can develop thought, mood, and behavioral disorders, including psychosis. Such effects may persist even after extended abstinence. Because cognitive deficits can affect [...]

25 01, 2018

Continuing Medical Education: Ascent to the Summit of the Pyramid

By |2018-04-18T11:40:22-07:00January 25th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

By Robin Stevenson, and Donald E. Moore Jr. Medical education is a continuum of 3 parts; undergraduate medical school education, postgraduate training, and continuing medical education (CME). CME differs from the other 2 educational components in that it has generally not been based on an explicit curriculum. Recently, CME has increasingly focused on addressing professional [...]

Go to Top